Searched for
PHARMA COM
USFDA concludes inspection at Jubilant HollisterStier's Spokane plant with 8 observationsJubilant Pharmova announced its US subsidiary, Jubilant HollisterStier LLC, underwent a USFDA inspection. The facility in Spokane, Washingt...- Diversity hiring jumps 21% despite slowdown in white-collar recruitment: founditWhite-collar hiring in India saw a slowdown in May 2026. However, diversity hiring experienced a substantial surge. This trend highlights a...
- Pankaj Pandey identifies defence, pharma and consumption as core stock picking themesIndian equities face a mixed outlook due to potential monsoon deficit and uneven corporate earnings. While rural-linked sectors may see pre...
- Piyush Goyal engages with over 50 industry leaders in New York to deepen India-US tradeIndia and the United States moved closer to deepening their trade ties as Union Minister of Commerce and Industry Piyush Goyal engaged with...
- IAIRO appoints AvenuesAI's CMD Vishal Mehta as Technical AdvisorThe Indian AI Research Organisation (IAIRO), a fast-rising institution at the centre of India's sovereign artificial intelligence ambitions...
- Diamonds in the dust? Retail investors unleash Rs 17,500 crore on 8 battered bluechip stocksRetail investors pumped an estimated Rs 17,539 crore into eight battered Nifty bluechip stocks during the March 2026 quarter, betting aggre...
- D-Street ends week in the green with war and peace on its mindFriday brought a wave of optimism to Indian stock markets, with notable weekly advancements. Nonetheless, investors remained watchful as ta...
- Rising bond yields, oil prices keeping markets on edge; selective bets still emerging: Pankaj PandeyGlobal markets are under pressure due to rising bond yields and geopolitical tensions. Higher crude oil prices are a key concern, potential...
- More companies may take confidential route to file IPO papersMore companies are choosing to file their initial public offering documents confidentially. This move is driven by uncertainty surrounding ...
- Stock Radar: Sun Pharma breaks out from falling trendline resistance to hit fresh 52-week high; time to buy?Sun Pharmaceutical Industries Ltd has broken out from a falling trendline resistance on weekly charts, hitting a fresh 52-week high. Expert...
- Pharma, Auto, and IT: Pankaj Pandey shares sectoral insights amid global challengesPankaj Pandey shares insights on Indian sectors facing US tariffs. He sees limited impact on pharma growth but potential benefits for Jubil...
- Buy Auro Pharma with a target of Rs 885: Ashwani Gujral'Auro Pharma is a 'BUY' call with a target of Rs 885 and a stop loss of Rs 850.'
- Buy Auro Pharma with a target of Rs 856: Ashwani Gujral'Auro Pharma is a 'BUY' call with a target of Rs 856 and a stop loss of Rs 820.'
- Buy Aurobindo Pharma Ltd with a target of Rs 915: Mitesh ThackerAurobindo Pharma Ltd is a 'BUY' call with a target of Rs 915 and a stop loss of Rs 849.
- Buy Aurobindo Pharma Ltd with a target of Rs 895: Ashwani GujralAurobindo Pharma Ltd is a 'BUY' call with a target of Rs 895 and a stop loss of Rs 860.
- Buy Sun Pharma with a target of Rs 895: Ashwani GujralSun Pharma is a 'BUY' call with a target of Rs 895 and a stop loss of Rs 860.
- Buy Ajanta Pharma with a target of Rs 2000: Prakash GabaAjanta Pharma is a 'BUY' call with a target of Rs 2000 and a stop loss of Rs 1680.
- Buy Aurobindo Pharma with a target of Rs 750: Prakash Gaba'Aurobindo Pharma is a 'BUY' call with a target of Rs 750 and a stop loss of Rs 692.'
- Sell Sun Pharma with target price of Rs 560: Mitesh ThackerSun Pharma is a 'SELL' with a target of Rs 560 and a stop loss of Rs 600.
- Avoid financials, buy FMCG and Pharma: Ashwani GujralFinancials and global cyclicals would lead this decline, metals may be even oil, so just try to keep away from these three sectors.
Load More
